Language:

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial

The Lancet (British edition), 2010-09, Vol.376 (9744), p.886-894 [Peer Reviewed Journal]

Elsevier Ltd ;2010 Elsevier Ltd ;2015 INIST-CNRS ;Copyright 2010 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 11-Sep 17, 2010 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(10)61259-7 ;PMID: 20801495 ;CODEN: LANCAO

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
Author: Böhm, Michael, Prof ; Swedberg, Karl, Prof ; Komajda, Michel, Prof ; Borer, Jeffrey S, Prof ; Ford, Ian, Prof ; Dubost-Brama, Ariane, MD ; Lerebours, Guy, MD ; Tavazzi, Luigi, Prof
Subjects: Adult ; Aged ; Benzazepines - administration & dosage ; Benzazepines - adverse effects ; Benzazepines - therapeutic use ; Benzazepines/administration & dosage/adverse effects/therapeutic use ; Biological and medical sciences ; Cardiac and Cardiovascular Systems ; Cardiology. Vascular system ; Cardiovascular Agents - administration & dosage ; Cardiovascular Agents - adverse effects ; Cardiovascular Agents - therapeutic use ; Cardiovascular Agents/administration & dosage/adverse effects/therapeutic ; Cardiovascular disease ; Cardiovascular diseases ; Chronic Disease ; Double-Blind Method ; Electrocardiography ; Epidemiology ; Female ; General aspects ; Heart ; Heart failure ; Heart Failure - complications ; Heart Failure - drug therapy ; Heart Failure - mortality ; Heart Failure - physiopathology ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Heart Failure/complications/drug therapy/mortality/physiopathology ; Heart rate ; Heart Rate - drug effects ; Humans ; Internal Medicine ; Kaplan-Meier Estimate ; Kaplan-Meiers Estimate ; Kardiologi ; Male ; Medical sciences ; Middle Aged ; Mortality ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Risk Factors ; Severity of Illness Index ; Sinoatrial Node - drug effects ; Studies ; Treatment Outcome ; use
Is Part Of: The Lancet (British edition), 2010-09, Vol.376 (9744), p.886-894
Description: Summary Background Raised resting heart rate is a marker of cardiovascular risk. We postulated that heart rate is also a risk factor for cardiovascular events in heart failure. In the SHIFT trial, patients with chronic heart failure were treated with the selective heart-rate-lowering agent ivabradine. We aimed to test our hypothesis by investigating the association between heart rate and events in this patient population. Methods We analysed cardiovascular outcomes in the placebo (n=3264) and ivabradine groups (n=3241) of this randomised trial, divided by quintiles of baseline heart rate in the placebo group. The primary composite endpoint was cardiovascular death or hospital admission for worsening heart failure. In the ivabradine group, heart rate achieved at 28 days was also analysed in relation to subsequent outcomes. Analysis adjusted to change in heart rate was used to study heart-rate reduction as mechanism for risk reduction by ivabradine directly. Findings In the placebo group, patients with the highest heart rates (≥87 beats per min [bpm], n=682, 286 events) were at more than two-fold higher risk for the primary composite endpoint than were patients with the lowest heart rates (70 to <72 bpm, n=461, 92 events; hazard ratio [HR] 2·34, 95% CI 1·84–2·98, p<0·0001). Risk of primary composite endpoint events increased by 3% with every beat increase from baseline heart rate and 16% for every 5-bpm increase. In the ivabradine group, there was a direct association between heart rate achieved at 28 days and subsequent cardiac outcomes. Patients with heart rates lower than 60 bpm at 28 days on treatment had fewer primary composite endpoint events during the study (n=1192; event rate 17·4%, 95% CI 15·3–19·6) than did patients with higher heart rates. The effect of ivabradine is accounted for by heart-rate reduction, as shown by the neutralisation of the treatment effect after adjustment for change of heart rate at 28 days (HR 0·95, 0·85–1·06, p=0·352). Interpretation Our analysis confirms that high heart rate is a risk factor in heart failure. Selective lowering of heart rates with ivabradine improves cardiovascular outcomes. Heart rate is an important target for treatment of heart failure. Funding Servier, France.
Publisher: Kidlington: Elsevier Ltd
Language: English
Identifier: ISSN: 0140-6736
EISSN: 1474-547X
DOI: 10.1016/S0140-6736(10)61259-7
PMID: 20801495
CODEN: LANCAO
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial

Elsevier Ltd ;2010 Elsevier Ltd ;2015 INIST-CNRS ;Copyright 2010 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 11-Sep 17, 2010 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(10)61259-7 ;PMID: 20801495 ;CODEN: LANCAO

Searching Remote Databases, Please Wait